Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 9;12(10):1521.
doi: 10.3390/antibiotics12101521.

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion

Andrea Marino  1   2 , Edoardo Campanella  3 , Stefano Stracquadanio  2 , Maddalena Calvo  4 , Giuseppe Migliorisi  4 , Alice Nicolosi  2 , Federica Cosentino  5 , Stefano Marletta  6 , Serena Spampinato  3 , Pamela Prestifilippo  7 , Stefania Stefani  2 , Bruno Cacopardo  1 , Giuseppe Nunnari  1
Affiliations
Review

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion

Andrea Marino et al. Antibiotics (Basel). .

Abstract

This comprehensive review examines the unique attributes, distinctions, and clinical implications of ceftazidime-avibactam (CAZ-AVI) and meropenem-vaborbactam (MEM-VAB) against difficult-to-treat Enterobacterales infections. Our manuscript explores these antibiotics' pharmacokinetic and pharmacodynamic properties, antimicrobial activities, in vitro susceptibility testing, and clinical data. Moreover, it includes a meticulous examination of comparative clinical and microbiological studies, assessed and presented to provide clarity in making informed treatment choices for clinicians. Finally, we propose an expert opinion from a microbiological and a clinical point of view about their use in appropriate clinical settings. This is the first review aiming to provide healthcare professionals with valuable insights for making informed treatment decisions when combating carbapenem-resistant pathogens.

Keywords: Gram-negative infections; carbapenem-resistant Enterobacterales; carbapenemases; ceftazidime–avibactam; meropenem–vaborbactam; new BL/BLICs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
CAZ-AVI chemical structure. Made with https://www.ebi.ac.uk/chembl/ (accessed on 20 Semptember 2023).
Figure 2
Figure 2
CAZ-AVI mechanism of action (A) and resistance mechanisms (B). Created using image databases https://stock.adobe.com/it/ (accessed on 15 September 2023) and https://pubchem.ncbi.nlm.nih.gov (accessed on 15 September 2023).
Figure 3
Figure 3
MEM-VAB chemical structure. Made with https://www.ebi.ac.uk/chembl/ (accessed on 25 September 2023).
Figure 4
Figure 4
MEM-VAB mechanism of action (A) and resistance mechanisms (B). Created using image databases https://stock.adobe.com/it/ (accessed on 15 September 2023) and https://pubchem.ncbi.nlm.nih.gov (accessed on 15 September 2023).
Figure 5
Figure 5
Schematization of avibactam and vaborbactam inhibition gene targets.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. European Centre for Disease Prevention and Control Antimicrobial Resistance in the EU/EEA (EARS-Net)—Annual Epidemiological Report. 2020. [(accessed on 2 March 2023)]. Available online: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobi....
    1. Kalil A.C., Klompas M. Ceftazidime-avibactam versus meropenem for the treatment of nosocomial pneumonia. Lancet Infect. Dis. 2018;18:229–231. doi: 10.1016/S1473-3099(17)30748-X. - DOI - PubMed
    1. Falcone M., Tiseo G., Carbonara S., Marino A., Di Caprio G., Carretta A., Mularoni A., Mariani M.F., Maraolo A.E., Scotto R., et al. Mortality Attributable to Bloodstream Infections Caused by Different Carbapenem-Resistant Gram-Negative Bacilli: Results from a Nationwide Study in Italy (ALARICO Network) Clin. Infect. Dis. 2023;76:2059–2069. doi: 10.1093/cid/ciad100. - DOI - PubMed
    1. Naimi T., Ringwald P., Besser R., Thompson S., Bell D. Antimicrobial Resistance. [(accessed on 2 March 2023)]. Available online: https://www.who.int/health-topics/antimicrobial-resistance.
    1. Gaibani P., Giani T., Bovo F., Lombardo D., Amadesi S., Lazzarotto T., Coppi M., Rossolini G.M., Ambretti S. Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing. Antibiotics. 2022;11:628. doi: 10.3390/antibiotics11050628. - DOI - PMC - PubMed

LinkOut - more resources